Form 4: Catalyst Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units
SEC Form 4 Filing
Catalyst Pharmaceuticals' Chief Operating and Scientific Officer, Steve Miller, was granted stock options and restricted stock units on November 21, 2024.
Summary
- Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, was granted 202,958 stock options with an exercise price of $21.12 on November 21, 2024.
- These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
- Miller also received 24,801 restricted stock units (RSUs) on the same date, which will convert to common stock upon vesting.
- Following these transactions, Miller directly owns 1,824,247 shares of common stock and 1,849,048 shares of common stock including the RSUs.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedule of the options encourages long-term commitment from the executive.
Industry Context
This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Equity grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Biogen, Amgen, and Gilead Sciences also use stock options and restricted stock units to align executive interests with shareholder value.
- The vesting schedule of three years is also typical for these types of grants.
Stakeholder Impact
- Shareholders may view this as a positive sign of aligning management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 11/21/2024 | Date of grant for stock options and restricted stock units. |
| 11/21/2025 | First vesting date for 1/3rd of the stock options. |
| 11/21/2026 | Second vesting date for 1/3rd of the stock options. |
| 11/21/2027 | Final vesting date for 1/3rd of the stock options. |
| 11/21/2031 | Expiration date of the stock options. |
| 11/25/2024 | Date the form was signed. |
Keywords
stock options, restricted stock units, executive compensation, insider trading, Catalyst Pharmaceuticals, CPRX, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.